Industry Overview

Cancer gene therapy market was valued at $4.3 billion in 2025 and is projected to reach $9.8 billion by 2035, growing at a CAGR of 8.7% during the forecast Period (2026-2035). The market is growing rapidly due to factors like increasing cancer incidence, advancements in genetic engineering, and the rise of personalized medicine. Key drivers include the growing number of approved therapies like CAR-T, extensive research and development, and strategic collaborations to enhance manufacturing capacity.

Market Dynamics

Rising Cancer Incidence and Unmet Therapeutic Need

One of the strongest engines for growth is the continually increasing global burden of cancer. As more patients develop treatment?resistant or advanced cancers, demand grows for therapies beyond conventional options (chemotherapy, radiation, surgery), which often fail for aggressive or relapsed cancers.  Gene therapy, particularly personalized and targeted approaches, addresses this. Moreover, this surge in incidence is not limited to a few cancer types: many forms (hematologic malignancies, solid tumors, rare or aggressive cancers) are being increasingly targeted in gene?therapy research and development. As a result, the growing patient population needing advanced therapies drives investment, R&D activity, and commercialization efforts in cancer gene therapy globally.

Advances in Gene?Editing, Vector Technologies, and Personalized Medicine

Technological progress has significantly boosted the feasibility and effectiveness of cancer gene therapy. Innovations such as gene?editing tools (CRISPR?Cas9), advanced viral vectors, and improved delivery systems enable precise targeting of genetic mutations driving cancer. This increases therapeutic efficiency, potentially reduces side effects, and opens the door to personalized medicine tailoring treatments to a patient’s genetic profile and cancer subtype. Additionally, such advances make it possible to expand from hematologic cancers (where much of the early success has been) to solid tumors, and to explore next?generation constructs (improved CAR?T, gene?modified immunotherapies, oncolytic virotherapy), thereby widening the addressable market.

Increased R&D Investments, Regulatory Approvals, and Commercialization Momentum

A third significant driver is the surge in financial and institutional support: growing R&D investments, strategic collaborations between biotech firms and large pharma, and a regulatory environment increasingly favorable to gene therapies. As more therapies demonstrate success in clinical trials, regulators (in North America and Europe) are granting approvals or breakthrough designations, which validate the approach and reduce risk for developers and investors. This in turn spurs more companies to enter the field, accelerates pipeline development, and supports scaling up manufacturing and commercialization capacities. Over time, as regulatory and manufacturing barriers ease, gene?based cancer therapies become more accessible encouraging broader adoption by hospitals and oncology centres globally.

Market Segmentation

• Based on the therapy, the market is segmented into gene transfer immunotherapy, oncolytic virotherapy, and gene induced immunotherapy.
• Based on the end-user, the market is segmented into hospitals, research institutes, and biotech companies.

Gene Transfer Immunotherapy Segment to Grow at a Considerable Market Share

Among all the segments in the global cancer gene therapy market, gene transfer immunotherapy emerges as the largest and leading segment by therapy type, owing to its significant adoption in treating various cancers through precise genetic modification of immune cells to target tumor cells effectively. On the end-user front, hospitals dominate the market, serving as the primary setting for administering advanced gene therapy treatments due to their established infrastructure, availability of specialized oncology departments, and direct patient access. The combination of the high efficacy of gene transfer immunotherapy and the central role of hospitals in delivering these therapies positions this segment at the forefront of market growth, driving the adoption of cancer gene therapies globally.

Hospitals: A Key Segment in Market Growth

In the global cancer gene therapy market, the hospitals segment is expected to witness the highest growth among all end-user categories during the forecast period. Hospitals serve as the primary point of care for cancer patients, providing both standard treatments and advanced gene therapy options. The increasing adoption of gene therapy in clinical settings, driven by advancements in personalized medicine, is a major factor propelling this segment. Hospitals are increasingly equipped with specialized infrastructure and trained personnel to administer complex gene-based therapies, making them the preferred choice for patients seeking cutting-edge cancer treatments.

Furthermore, the rising incidence of cancer globally, coupled with supportive reimbursement policies and government initiatives to improve access to advanced therapies, is further boosting the hospital segment. Compared to research institutes and biotech companies, which primarily focus on R&D and experimental applications, hospitals directly facilitate patient access to approved therapies, thereby driving significant market demand. This trend is particularly pronounced in developed regions such as North America and Europe, where well-established healthcare systems and higher healthcare spending enable faster adoption of innovative therapies. Overall, hospitals remain the key growth driver in the end-user segment of the global cancer gene therapy market, reflecting their central role in translating scientific advances into clinical practice.

Regional Outlook

The global cancer gene therapy market is further divided by geography, including North America (the US and Canada), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), and the Rest of the World (the Middle East & Africa, and Latin America).

North America Region to Hold a Substantial Growth Rate

North America, led by the US, is the dominant region in the global cancer gene therapy market, holding the largest market share and acting as the epicenter for innovation, clinical development, and commercialization. The US dominance is driven by several factors, including a well-established healthcare infrastructure, a strong presence of leading biotechnology and pharmaceutical companies, and robust government and private sector funding for cancer research and gene therapy development. The country hosts the majority of clinical trials for advanced therapies such as CAR-T, TCR therapies, oncolytic viruses, and gene-editing approaches, providing a competitive advantage in both innovation and regulatory approval speed.

Additionally, the US benefits from a favorable regulatory framework, including accelerated approval pathways and breakthrough therapy designations by the FDA, which encourage faster commercialization of novel gene therapies. Leading companies such as Novartis, Gilead Sciences, Bristol-Myers Squibb, bluebird bio, and Amgen are headquartered or heavily invested in the US, further consolidating their leadership in the market. Rising cancer prevalence, increasing patient awareness, and higher healthcare expenditure also contribute to the widespread adoption of gene therapies. Collectively, these factors ensure that the US continues to dominate the global cancer gene therapy landscape, both in terms of market size and technological advancement, setting a benchmark for other regions such as Europe and the Asia-Pacific.

Market Players Outlook

The major companies operating in the global cancer gene therapy market include Amgen Inc., Bluebird Bio, Inc., Bristol-Myers Squibb (BMS), Gilead Sciences, Inc., Novartis AG, among others. Market players are leveraging partnerships, collaborations, mergers, and acquisitions to expand their businesses and develop innovative products to maintain their market positioning.

Recent Developments

• In November 2025, the Indian government unveiled three significant innovations during the Emerging Science, Technology & Innovation Conclave (ESTIC2025), QSIP, a quantum security chip; a 25-qubit quantum processing unit (QPU), and NexCAR19, the country's first indigenous CAR-T cell therapy. Developed by ImmunoACT, a spin-off from IIT Bombay, NexCAR19 represents a breakthrough in cancer treatment, particularly for patients with Acute Lymphocytic Leukemia, and was supported by the Department of Biotechnology (DBT) and the Biotechnology Industry Research Assistance Council (BIRAC). This living drug emphasizes affordability and accessibility in gene therapies while maintaining patient safety and scientific integrity.
• In August 2024, the FDA approved Tecelra (afamitresgene autoleucel), the first gene therapy for adults with unresectable or metastatic synovial sarcoma following prior chemotherapy. The therapy is specifically for patients with certain HLA antigen positivity and MAGE-A4-expressing tumors, confirmed by FDA-authorized diagnostics. Synovial sarcoma is a rare soft tissue cancer, affecting approximately 1,000 individuals annually in the US, mostly adult males in their 30s or younger. Tecelra is an autologous T cell receptor gene therapy, modifying a patient's T cells to target the MAGE-A4 antigen, and is given as a single intravenous dose.

The Report Covers

• Market value data analysis for 2025 and forecast to 2035.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global cancer gene therapy market. Based on the availability of data, information related to new products and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.